Shares in Irish clinical trials firm Icon remain 28pc lower than where they were trading just a week before the group warned in February that it was engaged in an “ongoing internal investigation” into certain accounting practices and controls.
Stock is still 43pc lower than in January
The firm behind Coole Swan has secured agreements with loan note holders to convert over €3m of debt into shares as the Irish cream liqueur brand aims to turn a profit next year.